Compare ACP & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACP | KALV |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.0M | 551.2M |
| IPO Year | N/A | N/A |
| Metric | ACP | KALV |
|---|---|---|
| Price | $5.49 | $16.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $27.83 |
| AVG Volume (30 Days) | 337.9K | ★ 956.5K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 17.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,426,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $204.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.55 | $7.30 |
| 52 Week High | $7.17 | $17.30 |
| Indicator | ACP | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 55.83 | 60.08 |
| Support Level | $5.35 | $15.12 |
| Resistance Level | $5.48 | $16.45 |
| Average True Range (ATR) | 0.05 | 0.88 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 79.41 | 82.78 |
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.